JP2009544724A5 - - Google Patents

Download PDF

Info

Publication number
JP2009544724A5
JP2009544724A5 JP2009521935A JP2009521935A JP2009544724A5 JP 2009544724 A5 JP2009544724 A5 JP 2009544724A5 JP 2009521935 A JP2009521935 A JP 2009521935A JP 2009521935 A JP2009521935 A JP 2009521935A JP 2009544724 A5 JP2009544724 A5 JP 2009544724A5
Authority
JP
Japan
Prior art keywords
antigen
composition
cytokine
csf
cytokines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009521935A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009544724A (ja
Filing date
Publication date
Priority claimed from US11/492,418 external-priority patent/US20070025958A1/en
Application filed filed Critical
Publication of JP2009544724A publication Critical patent/JP2009544724A/ja
Publication of JP2009544724A5 publication Critical patent/JP2009544724A5/ja
Pending legal-status Critical Current

Links

JP2009521935A 2006-07-25 2007-07-24 ワクチン免疫療法 Pending JP2009544724A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/492,418 US20070025958A1 (en) 2000-10-27 2006-07-25 Vaccine immunotherapy
PCT/US2007/074156 WO2008014220A2 (en) 2006-07-25 2007-07-24 Vaccine immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013140691A Division JP2013189480A (ja) 2006-07-25 2013-07-04 ワクチン免疫療法

Publications (2)

Publication Number Publication Date
JP2009544724A JP2009544724A (ja) 2009-12-17
JP2009544724A5 true JP2009544724A5 (enExample) 2010-08-19

Family

ID=38982244

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2009521935A Pending JP2009544724A (ja) 2006-07-25 2007-07-24 ワクチン免疫療法
JP2013140691A Withdrawn JP2013189480A (ja) 2006-07-25 2013-07-04 ワクチン免疫療法
JP2015222533A Expired - Fee Related JP6162778B2 (ja) 2006-07-25 2015-11-12 ワクチン免疫療法
JP2017117390A Pending JP2017155059A (ja) 2006-07-25 2017-06-15 ワクチン免疫療法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2013140691A Withdrawn JP2013189480A (ja) 2006-07-25 2013-07-04 ワクチン免疫療法
JP2015222533A Expired - Fee Related JP6162778B2 (ja) 2006-07-25 2015-11-12 ワクチン免疫療法
JP2017117390A Pending JP2017155059A (ja) 2006-07-25 2017-06-15 ワクチン免疫療法

Country Status (7)

Country Link
US (3) US20070025958A1 (enExample)
EP (2) EP2056861A4 (enExample)
JP (4) JP2009544724A (enExample)
AU (1) AU2007276835B2 (enExample)
CA (1) CA2694428C (enExample)
MX (1) MX2009000934A (enExample)
WO (1) WO2008014220A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070154399A1 (en) * 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
CA2950109C (en) 2000-10-27 2019-02-19 John W. Hadden Vaccine immunotherapy for immune suppressed patients
WO2009070639A1 (en) 2007-11-28 2009-06-04 Irx Therapeutics, Inc. Method of increasing immunological effect
CA2758834C (en) * 2008-04-14 2017-11-07 Irx Therapeutics, Inc. Primary cell derived biologic modified manufacturing process
US9695397B2 (en) 2008-10-01 2017-07-04 Immunovative Therapies Ltd. Th1 vaccination priming for active immunotherapy
AU2009251277A1 (en) * 2008-05-29 2009-12-03 Irx Therapeutics, Inc. Mechanism of action of primary cell derived biologic
AU2013203561B2 (en) * 2009-05-15 2015-11-26 Irx Therapeutics, Inc. Vaccine immunotherapy
AU2010248761B2 (en) * 2009-05-15 2016-02-11 Irx Therapeutics, Inc. Vaccine immunotherapy
AU2010307075B2 (en) 2009-10-12 2014-12-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Granulysin in immunotherapy
CN107050430B (zh) 2009-12-08 2021-10-15 伊尔克斯治疗有限公司 逆转朗格汉斯细胞免疫抑制的方法
WO2012021609A2 (en) * 2010-08-12 2012-02-16 Ulrik Mouritzen Neoadjuvant treatment of cancer with proleukin
WO2012037551A2 (en) * 2010-09-17 2012-03-22 Irx Therapeutics, Inc. Primary cell-derived biologic and wt1 synthetic long peptide vaccine
JP6124460B2 (ja) * 2012-02-16 2017-05-10 国立大学法人 岡山大学 融合タンパク質を含む癌治療用医薬組成物
CN104122710B (zh) * 2013-04-27 2017-08-08 北京京东方光电科技有限公司 一种显示面板及其制造方法
WO2018161038A1 (en) * 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Il12 compositions and methods for immunotherapy
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
US11464798B2 (en) 2017-05-11 2022-10-11 Theralase Technologies Inc. Vaccine containing cancer cells inactivated by photodynamic treatment with metal-based coordination complexes, and immunotherapy method using same
CN110101843A (zh) * 2018-02-01 2019-08-09 北京科诺科服生物科技有限公司 一种抗肿瘤蛋白质及其应用
WO2020073044A1 (en) * 2018-10-05 2020-04-09 Czerniecki Brian J Combination therapy for treating cancer
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2160326B1 (enExample) * 1971-11-19 1975-02-07 Anvar
US4079127A (en) * 1976-10-28 1978-03-14 Board Of Regents Of The University Of Texas Thymosin alpha 1
US4116951A (en) * 1977-04-22 1978-09-26 Hoffmann-La Roche Inc. [Asn2 ]-thymosin α1 and analogs thereof
US4148788A (en) * 1978-01-23 1979-04-10 Hoffmann-La Roche Inc. Synthesis of thymosin α1
DE2919592A1 (de) * 1979-05-15 1981-01-15 Max Planck Gesellschaft Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon
US4470926A (en) * 1980-01-18 1984-09-11 Max-Planck-Gesellschaft zur F/o/ rderung der Wissenschaften e.V. Medicaments containing thymosin alpha 1 fragments and having an immunostimulant action, and fragments of thymosin alpha 1
DE3100974A1 (de) * 1980-01-18 1982-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Thymosin(alpha)(pfeil abwaerts)1(pfeil abwaerts)-fragmente enthaltende arzneimittel mit immunregulierender wirkung, und thymosin(alpha)(pfeil abwaerts)1(pfeil abwaerts)-fragmente
US4612365A (en) * 1980-03-25 1986-09-16 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften Medicaments containing alpha 1-thymosin and having an immuno regulatory action and alpha 1-thymosin fragments
US4293455A (en) * 1980-04-07 1981-10-06 Rockefeller University N.sup.α -Desacetylthymosinα1 and process
IL62903A0 (en) 1980-05-22 1981-07-31 Deutsches Krebsforsch Method for the production of interferon ii and stimulated clones for the carrying out of the method
US4390623A (en) * 1980-10-02 1983-06-28 Hooper Trading Company Serum-free and mitogen-free T-cell growth factor and process for making same
US4475196A (en) * 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4464355A (en) * 1981-03-26 1984-08-07 Hooper Trading Co. Serum-free and mitogen-free T-cell growth factor and process for making same
US4448879A (en) * 1981-03-26 1984-05-15 Hooper Trading Company High yield process for in vitro production of serum-free and mitogen-free interleukin-2
US4447233A (en) * 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4406830A (en) * 1981-04-17 1983-09-27 Shanksville Corporation, N.V. Regulatory glycoprotein for immune response and the use thereof in the production of T-cell growth factor
DE3120912A1 (de) * 1981-05-26 1982-12-16 Hoechst Ag, 6000 Frankfurt Verfahren zur herstellung von p-nitrophenetol
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
EP0091539B2 (en) 1982-03-31 1996-11-27 Ajinomoto Co., Inc. Gene coding for interleukin-2 polypeptide, recombinant DNA carrying said gene, cell lines possessing the recombinant DNA,and method for producing interleukin-2 using said cells
US4447224A (en) * 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) * 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4504415A (en) * 1983-04-04 1985-03-12 Hoffman-La Roche Inc. Synthesis of thymosin α1 and desacetyl thymosin α1
US4486194A (en) * 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4614731A (en) * 1983-09-15 1986-09-30 Hoffmann-La Roche Inc. Peptide having immunopotentiating activity similar to thymosin alpha1
US4659694A (en) * 1983-10-27 1987-04-21 Hoffmann-La Roche Inc. Prothymosin alpha
US4716148A (en) * 1984-08-13 1987-12-29 Hoffman-La Roche Inc. Prothymosin alpha
US5643565A (en) * 1985-09-20 1997-07-01 Chiron Corporation Human IL-2 as a vaccine adjuvant
US5100664A (en) * 1985-09-20 1992-03-31 Cetus Corporation Human IL-2 as a vaccine adjuvant
US5503841A (en) * 1985-09-20 1996-04-02 Cetus Oncology Corporation Human IL-2 as a vaccine adjuvant
US5098702A (en) * 1986-04-09 1992-03-24 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
AU7397887A (en) 1986-05-09 1987-12-01 Sloan-Kettering Institute For Cancer Research Lipopolysaccharide and natural factor compositions for anti-tumor therapy and method of treatment
US4992367A (en) 1986-05-12 1991-02-12 Hoffmann-La Roche Inc. Enhanced expression of human interleukin-2 in mammalian cells
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4925678A (en) 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
US5080646A (en) 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
US5376369A (en) * 1987-11-03 1994-12-27 Syntex (U.S.A.) Inc. Vaccine adjuvant
SE8801426D0 (sv) 1988-04-15 1988-04-15 Ulf Rothman Forfarande och medel for blodbehandling
CA2003455C (en) * 1988-11-23 2000-02-22 Craig B. Thompson Immunotherapy involving cd28 stimulation
US6534055B1 (en) * 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5167616A (en) * 1989-12-14 1992-12-01 Alza Corporation Iontophoretic delivery method
IT1238231B (it) 1989-12-18 1993-07-12 Consiglio Nazionale Ricerche Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori
US5225182A (en) 1991-10-31 1993-07-06 Sharma Yash P Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system
US5503828A (en) * 1992-02-10 1996-04-02 Interferon Sciences, Inc. Alpha interferon composition and method for its production from human peripheral blood leukocytes
MX9304089A (es) * 1992-07-08 1994-01-31 Schering Corp Uso de gm-csf como una vacuna adyuvante.
CN1094310A (zh) 1992-12-15 1994-11-02 托马斯·C·梅里根 人体免疫缺陷性病毒感染用组合式化学疗法
US5747024A (en) * 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
CA2164226C (en) 1993-06-04 2011-02-08 Carl H. June Methods for selectively stimulating proliferation of t cells
AU686660B2 (en) * 1993-08-11 1998-02-12 Jenner Technologies Prostatic cancer vaccine
CN1044781C (zh) 1994-02-05 1999-08-25 丹东市生物制品免疫技术应用研究中心 复方免疫抗生素
DE4412794A1 (de) * 1994-04-14 1995-12-14 Univ Ludwigs Albert Verfahren zur Herstellung von dendritischen Zellen, so erhaltene Zellen und Behälter zur Durchführung dieses Verfahrens
DE69533941T2 (de) 1994-11-17 2005-12-29 University Of South Florida, Tampa Verfahren zur herstellung eines arzneimittels zur behandlung des sekundärimmunmangels
US5632983A (en) 1994-11-17 1997-05-27 University Of South Florida Method for treating secondary immunodeficiency
EP0826043B1 (en) 1995-05-04 2003-07-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE NAVY Methods for modulating t cell survival by modulating bcl-xl protein level
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
AP964A (en) 1996-02-21 2001-05-11 Julianna Lisziewicz Methods and compositions for protective and therapeutic genetic immunisation.
US5849589A (en) * 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6017527A (en) * 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
US5849307A (en) * 1997-03-26 1998-12-15 The Picower Institute For Medical Research Vaccine adjuvant
WO1999020788A1 (en) 1997-10-17 1999-04-29 University Of South Florida Method to diagnose and monitor cellular immune deficiencies
ATE428769T1 (de) * 1997-10-27 2009-05-15 Univ Rockefeller Methode und zusammensetzung zur herstellung von reifen dendritischen zellen
JP2002502884A (ja) 1998-02-12 2002-01-29 アメリカン・サイアナミド・カンパニー インターロイキン−１２および単純ヘルペスウイルス抗原を含んでなるワクチン
US20050124645A1 (en) * 1998-04-20 2005-06-09 Finkel Terri H. Methods and compositions for increasing CD4lymphocyte immune responsiveness
EP0974357A1 (en) * 1998-07-16 2000-01-26 Schering-Plough Chemokines as adjuvants of immune response
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
GB9827103D0 (en) 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
US6017537A (en) * 1998-12-18 2000-01-25 Connaught Laboratories, Inc. Formyl methionyl peptide vaccine adjuvant
US6350589B1 (en) * 1998-12-31 2002-02-26 Viragen, Inc. Compositions of highly-purified natural mixtures of type I interferon derived from leukocytes and methods
US6667175B1 (en) 1999-06-15 2003-12-23 The Trustees Of Columbia University Generation of antigen specific T suppressor cells for treatment of rejection
US7056503B2 (en) * 1999-08-19 2006-06-06 Regents Of The University Of Michigan Enclosures housing cell-coated supports for treating tumors
US6406699B1 (en) 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
HK1052372A1 (zh) * 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
WO2001097841A2 (en) * 2000-06-22 2001-12-27 American Cyanamid Company Qs-21 and il-12 as an adjuvant combination
US7182942B2 (en) 2000-10-27 2007-02-27 Irx Therapeutics, Inc. Vaccine immunotherapy for immune suppressed patients
US20070025958A1 (en) * 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
US20070031372A1 (en) * 2004-08-05 2007-02-08 Hadden John W Vaccine immunotherapy for immune suppressed patients
US20060194242A1 (en) * 2000-10-27 2006-08-31 Hadden John W Immunotherapy for immune suppressed patients
CA2950109C (en) * 2000-10-27 2019-02-19 John W. Hadden Vaccine immunotherapy for immune suppressed patients
US20070154399A1 (en) 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
JP2005510491A (ja) * 2001-10-26 2005-04-21 イミュノ−アールエックス， インコーポレイテッド 免疫抑制を逆転させるための免疫治療
DE10154579A1 (de) * 2001-11-07 2003-05-28 Medigene Ag Topikale Verwendung von Cytokinen und Chemokinen zur Behandlung von viralen oder mykotischen Hauterkrankungen oder Tumorerkrankungen
WO2003061566A2 (en) 2002-01-24 2003-07-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anti-cancer combination and use thereof
RS20050501A (sr) * 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polimerni konjugati citokina,hemokina,faktora rasta, polipeptidnih hormona i njihovih antagonista sa očuvanom aktivnošću vezivanja receptora
CA2521744A1 (en) * 2003-04-15 2004-10-28 Sanofi Pasteur Limited Tumor antigens bfa-5 for prevention and/or treatment of cancer
US6896879B2 (en) * 2003-07-03 2005-05-24 Cel-Sci Corporation Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture
WO2005077048A2 (en) 2004-02-09 2005-08-25 The Johns Hopkins University Immune modulation by regulating expression of the “minor” gene in immune dendritic cells
GB0409799D0 (en) * 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
ES2553133T3 (es) 2004-06-04 2015-12-04 Cel-Sci Corporation Método de modificación de la proporción de CD4/CD8 y del infiltrado celular mononuclear en un tumor
JP2008502605A (ja) 2004-06-16 2008-01-31 スマート ドラッグ システムズ インコーポレイティド 徐放性ワクチン組成物
CN101052709B (zh) 2004-10-25 2012-06-27 贝勒研究院 装载热激黑素瘤细胞体的树突细胞
US20070065415A1 (en) 2005-09-16 2007-03-22 Kleinsek Donald A Compositions and methods for the augmentation and repair of defects in tissue
JP2009508650A (ja) 2005-09-21 2009-03-05 ダスク テクノロジーズ， エルエルシー 臓器および組織機能のための方法および組成
EP1957634A4 (en) 2005-12-08 2010-01-27 Northwest Biotherapeutics Inc COMPOSITIONS AND METHODS OF INDUCING THE ACTIVATION OF UNREFERENCE MONOCYTIC DENDRITE CELLS
WO2007130826A2 (en) * 2006-05-04 2007-11-15 Ge Healthcare Bio-Sciences Ab Separation of cells
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
WO2008133983A1 (en) 2007-04-25 2008-11-06 Immurx, Inc. Adjuvant combinations of nkt activator, cd40 agonist, and optional antigen, the use through inducing synergistic cellular immunity
US20090010966A1 (en) * 2007-06-21 2009-01-08 Angelica Therapeutics, Inc. Modified diphtheria toxins
WO2009070639A1 (en) 2007-11-28 2009-06-04 Irx Therapeutics, Inc. Method of increasing immunological effect
CA2758834C (en) 2008-04-14 2017-11-07 Irx Therapeutics, Inc. Primary cell derived biologic modified manufacturing process
AU2009251277A1 (en) 2008-05-29 2009-12-03 Irx Therapeutics, Inc. Mechanism of action of primary cell derived biologic
AU2010248761B2 (en) 2009-05-15 2016-02-11 Irx Therapeutics, Inc. Vaccine immunotherapy
CN107050430B (zh) * 2009-12-08 2021-10-15 伊尔克斯治疗有限公司 逆转朗格汉斯细胞免疫抑制的方法
WO2012037551A2 (en) 2010-09-17 2012-03-22 Irx Therapeutics, Inc. Primary cell-derived biologic and wt1 synthetic long peptide vaccine
US20130243423A1 (en) * 2011-07-26 2013-09-19 Ziqiang He Ethernet hub and method of use

Similar Documents

Publication Publication Date Title
Maniati et al. Up for Mischief? IL-17/Th17 in the tumour microenvironment
Bagheri et al. CXCL-10: a new candidate for melanoma therapy?
Kurzrock Cytokine deregulation in cancer
JP2005530716A5 (enExample)
Sauder Immunomodulatory and pharmacologic properties of imiquimod
Yuzhalin et al. Interleukin-12: clinical usage and molecular markers of cancer susceptibility
Asadullah et al. Cytokines: interleukin and interferon therapy in dermatology
JP2012087150A5 (enExample)
WO2008014220A3 (en) Vaccine immunotherapy
JP2002524537A5 (enExample)
EP2172212A3 (en) Novel immunotherapy against several tumors including neuronal and brain tumors
EA201000209A1 (ru) Новая иммунотерапия против нейрональных опухолей и опухолей головного мозга
WO2000055345A3 (en) Therapy of cancer by insect cells containing recombinant baculovirus encoding genes
WO2001095919A3 (en) A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
MXPA02000490A (es) Produccion de virus sincitiales respiratorios recombinantes, que expresan moleculas inmunomoduladoras.
Zhao et al. Nifuroxazide prompts antitumor immune response of TCL-loaded DC in mice with orthotopically-implanted hepatocarcinoma
JP2007501798A5 (enExample)
KR100788930B1 (ko) 항암 조성물
Ito et al. Screening of cytokines to enhance vaccine effects of heat shock protein 70-rich tumor cell lysate
Hofbauer et al. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate
Autenshlyus et al. Cytokine pattern of the breast tumor supernatant
An et al. Advances in IL-2 family cytokine-based cancer therapies: overcoming challenges through molecular engineering and delivery strategies
Pérez-Torres et al. Hematological effects, serum, and pulmonary cytokine profiles in a melanoma mouse model treated with GK1
Jin et al. Adenovirus-mediated gene transfer of interleukin-23 shows prophylactic but not therapeutic antitumor effects
Tsujiuchi et al. Elevated expression of transforming growth factor βs and the tumor necrosis factor family in lung adenocarcinomas inducedby N-nitrosobis (2-hydroxypropyl) amine in rats